<DOC>
	<DOC>NCT01519284</DOC>
	<brief_summary>To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.</brief_summary>
	<brief_title>Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic</brief_title>
	<detailed_description>Single-centre, double-blind, randomised, parallel-group study in 80 young male and female healthy subjects.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Able and willing to give written informed consent. Male or female subjects aged between 18 and 45 years, inclusive. Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive. Healthy as determined by prestudy medical history, physical examination, vital signs, complete neurological examination and 12lead ECG. Negative tests for HBsAg, antiHCVAb and HIV1 and HIV2 Ab at screening. Clinical laboratory test results clinically acceptable at screening and admission to the treatment period. Negative screen for alcohol and drugs of abuse at screening and admission to the treatment period. Nonsmokers or exsmokers for at least 3 months. (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: intrauterine device (by the subject) and condoms (by the partner) or diaphragm (by the subject) and condoms (by the partner) or spermicide (by the subject) and condoms (by the partner). (If female) She had a negative urine pregnancy test at screening and admission to the treatment period. Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders. Clinically relevant surgical history. Any abnormality in the coagulation tests. Any abnormality in the liver function tests. A history of relevant atopy or drug hypersensitivity. A history or presence of narrowangle glaucoma. A suspicious undiagnosed skin lesions or a history of melanoma. History of alcoholism or drug abuse. Consumed more than 14 units of alcohol a week. Significant infection or known inflammatory process at screening or admission to the treatment period. Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to the treatment period. Had used nonselective monoamine oxidase (MAO) inhibitors within 2 weeks of admission to the treatment period. Had used medicines within 2 weeks of admission to the treatment period that may have affected the safety or other study assessments, in the investigator's opinion. Had previously received BIA 91067. Had used any investigational drug or participated in any clinical trial within 6 months prior to screening. Had participated in more than 2 clinical trials within the 12 months prior to screening. Had donated or received any blood or blood products within the 3 months prior to screening. Vegetarians, vegans or had medical dietary restrictions. Cannot communicate reliably with the investigator. Unlikely to cooperate with the requirements of the study. Unwilling or unable to gave written informed consent. (If female) She was pregnant or breastfeeding. (If female) She was of childbearing potential and she did not use an approved effective contraceptive method or she used oral contraceptives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>